PMID- 29760706
OWN - NLM
STAT- MEDLINE
DCOM- 20190610
LR  - 20190613
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - Complement-Opsonized HIV-1 Alters Cross Talk Between Dendritic Cells and Natural 
      Killer (NK) Cells to Inhibit NK Killing and to Upregulate PD-1, CXCR3, and CCR4 
      on T Cells.
PG  - 899
LID - 10.3389/fimmu.2018.00899 [doi]
LID - 899
AB  - Dendritic cells (DCs), natural killer (NK) cells, and T cells play critical roles 
      during primary HIV-1 exposure at the mucosa, where the viral particles become 
      coated with complement fragments and mucosa-associated antibodies. The 
      microenvironment together with subsequent interactions between these cells and 
      HIV at the mucosal site of infection will determine the quality of immune 
      response that ensues adaptive activation. Here, we investigated how complement 
      and immunoglobulin opsonization influences the responses triggered in DCs and NK 
      cells, how this affects their cross talk, and what T cell phenotypes are induced 
      to expand following the interaction. Our results showed that DCs exposed to 
      complement-opsonized HIV (C-HIV) were less mature and had a poor ability to 
      trigger IFN-driven NK cell activation. In addition, when the DCs were exposed to 
      C-HIV, the cytotolytic potentials of both NK cells and CD8 T cells were markedly 
      suppressed. The expression of PD-1 as well as co-expression of negative immune 
      checkpoints TIM-3 and LAG-3 on PD-1 positive cells were increased on both CD4 as 
      well as CD8 T cells upon interaction with and priming by NK-DC cross talk 
      cultures exposed to C-HIV. In addition, stimulation by NK-DC cross talk cultures 
      exposed to C-HIV led to the upregulation of CD38, CXCR3, and CCR4 on T cells. 
      Together, the immune modulation induced during the presence of complement on 
      viral surfaces is likely to favor HIV establishment, dissemination, and viral 
      pathogenesis.
FAU - Ellegard, Rada
AU  - Ellegard R
AD  - Division of Molecular Virology, Department of Clinical and Experimental Medicine, 
      Linkoping University, Linkoping, Sweden.
FAU - Khalid, Mohammad
AU  - Khalid M
AD  - Division of Molecular Virology, Department of Clinical and Experimental Medicine, 
      Linkoping University, Linkoping, Sweden.
AD  - Department of Pharmaceutics, College of Pharmacy, King Khalid University, 
      Asir-Abha, Saudi Arabia.
FAU - Svanberg, Cecilia
AU  - Svanberg C
AD  - Division of Molecular Virology, Department of Clinical and Experimental Medicine, 
      Linkoping University, Linkoping, Sweden.
FAU - Holgersson, Hanna
AU  - Holgersson H
AD  - Division of Molecular Virology, Department of Clinical and Experimental Medicine, 
      Linkoping University, Linkoping, Sweden.
FAU - Thoren, Ylva
AU  - Thoren Y
AD  - Division of Molecular Virology, Department of Clinical and Experimental Medicine, 
      Linkoping University, Linkoping, Sweden.
FAU - Wittgren, Mirja Karolina
AU  - Wittgren MK
AD  - Division of Molecular Virology, Department of Clinical and Experimental Medicine, 
      Linkoping University, Linkoping, Sweden.
FAU - Hinkula, Jorma
AU  - Hinkula J
AD  - Division of Molecular Virology, Department of Clinical and Experimental Medicine, 
      Linkoping University, Linkoping, Sweden.
FAU - Nystrom, Sofia
AU  - Nystrom S
AD  - Division of Molecular Virology, Department of Clinical and Experimental Medicine, 
      Linkoping University, Linkoping, Sweden.
AD  - Clinical Immunology and Transfusion Medicine, Department of Clinical and 
      Experimental Medicine, Linkoping University, Linkoping, Sweden.
FAU - Shankar, Esaki M
AU  - Shankar EM
AD  - Division of Infection Biology, Department of Life Sciences, Central University of 
      Tamil Nadu, Thiruvarur, India.
AD  - Center of Excellence for Research in AIDS (CERiA), University of Malaya, Lembah 
      Pantai, Kuala Lumpur, Malaysia.
AD  - Department of Microbiology, Central University of Tamil Nadu, Thiruvarur, India.
FAU - Larsson, Marie
AU  - Larsson M
AD  - Division of Molecular Virology, Department of Clinical and Experimental Medicine, 
      Linkoping University, Linkoping, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180430
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (CCR4 protein, human)
RN  - 0 (CXCR3 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (Receptors, CCR4)
RN  - 0 (Receptors, CXCR3)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Complement System Proteins/*immunology
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/*immunology
MH  - HIV Infections/*immunology
MH  - HIV-1/*immunology
MH  - Humans
MH  - Killer Cells, Natural/*immunology
MH  - Lymphocyte Activation/immunology
MH  - Programmed Cell Death 1 Receptor/biosynthesis/immunology
MH  - Receptor Cross-Talk/immunology
MH  - Receptors, CCR4/biosynthesis/immunology
MH  - Receptors, CXCR3/biosynthesis/immunology
MH  - T-Lymphocytes/*immunology
MH  - Up-Regulation
PMC - PMC5936988
OTO - NOTNLM
OT  - CCR4
OT  - CXCR3
OT  - HIV
OT  - checkpoint inhibitors
OT  - complement
OT  - cross talk
OT  - dendritic cells
OT  - natural killer cells
EDAT- 2018/05/16 06:00
MHDA- 2018/05/16 06:01
PMCR- 2018/01/01
CRDT- 2018/05/16 06:00
PHST- 2018/01/26 00:00 [received]
PHST- 2018/04/11 00:00 [accepted]
PHST- 2018/05/16 06:00 [entrez]
PHST- 2018/05/16 06:00 [pubmed]
PHST- 2018/05/16 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.00899 [doi]
PST - epublish
SO  - Front Immunol. 2018 Apr 30;9:899. doi: 10.3389/fimmu.2018.00899. eCollection 
      2018.